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Prevalence and clinical value of IgA and hidden rheumatoid factors in 
juvenile rheumatoid arthritis. 
INTRODUCTION 
Juvenile rheumatoid arthritis (JRA) is associated with 
certain generalized abnormalities of the immune 
system. A number of circulating autoantibodies 
including rheumatoid factors (RFs) are found in the 
serum of most patients with JRA 1. 
Rheumatoid factors are a group of antibodies that 
react with the Fc portion of immunoglobulin G (IgG). 
Rheumatoid factors detected by standard 
agglutination techniques such as latex agglutination 
or the sheep cell agglutination tests are IgM. A small 
subgroup of patients with JRA has positive RFs. 
Original article 
Background: Juvenile rheumatoid arthritis (JRA) is so difficult to be 
diagnosed early and a small subgroup of patients has positive IgM rheumatoid 
factor (RF) detected by the standard agglutination techniques.  
Objective: To investigate the prevalence of IgA and hidden RFs among 
patients with JRA, to evaluate their diagnostic value in comparison to classic 
RF and to outline their relation to disease activity, severity as well as to 
therapy. 
Methods: The study included 46 patients with JRA (31 females and 15 males). 
Thirty patients had polyarticular JRA, 9 had oligoarticular JRA and 7 had 
systemic-onset JRA. Twelve patients had active disease. Thirteen systemic 
lupus erythematosus patients and 32 healthy subjects were studied as controls. 
Evaluation was carried out clinically and radiologically (using modified 
Larsen scoring). Laboratory investigations included CBC, ESR, classic IgM 
RF (latex agglutination), ANA (indirect immunofluorescence), IgA-RF (ELISA) 
and hidden RF seropositivity (ion exchange chromatography). 
Results: All JRA patients had significantly higher IgA-RF (121.5 ± 195.4 
mg/dL) and positivity of hidden RF (56.5%) than lupus (14 ± 6.6 mg/dL and 
7.7% respectively) and healthy controls (13.7 ± 6.2 mg/dL and 0% 
respectively). Classic IgM RF had only 10.9% sensitivity in diagnosing JRA. 
IgA and hidden RFs had higher sensitivities (50% and 56.5% respectively). 
Specificity, positive and negative predictive values of IgA-RF were 97.7%, 
95.8% and 65.7% and for hidden RF, they were 95.5%, 92.9% and 68.3%. 
Interestingly, combined positivity of IgA and hidden RFs had 100% specificity 
and positive predictive value for JRA. Classic RF did not correlate with 
disease activity and severity in terms of ESR, activity score and Larsen Index. 
In contrast, patients with active disease had significantly higher value of IgA-
RF and positivity of hidden RF than those with quiescent disease. Also, IgA-
RF had significant positive correlation with ESR, activity score and Larsen 
index. Similarly, patients with positive hidden RF had significantly higher 
values of ESR, activity score and Larsen index than those with negative hidden 
RF. Steroid therapy was associated with significantly higher level of IgA-RF 
and positivity of hidden RF, perhaps related to disease severity. 
Conclusion: IgA and hidden RFs are more sensitive tests in diagnosing JRA 
than classic IgM RF. Also, the combined positivity of IgA and hidden RFs can 
confirm the diagnosis of JRA in doubtful cases. The fact that IgA and hidden 
RFs gave positive results in the meantime that classic RF was negative, 
together with their significant relation to disease activity and severity 
highlights their clinical value as reliable laboratory markers of JRA. 
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Other RFs of IgG, IgA and IgE classes can also be 
identified by methods other than agglutination tests 2. 
To date, the diagnosis of JRA has been based on 
the American College of Rheumatology (ACR) 
criteria and RFs are the only autoantibodies included 
among the classification criteria 1. Raised titres of 
IgA-RF were detected in patients with rheumatoid 
arthritis and it was significantly associated with 
disease activity and worse functional capacity 3. 
Similarly, Hidden RF was detected in the IgM 
containing fraction after separation of the sera of 
patients with JRA at an acid pH 4,5.  
This work was conducted to determine the 
prevalence of IgA and hidden rheumatoid factors 
among patients with JRA and to evaluate their overall 
performance as diagnostic tests in this disease. The 
study also aimed at outlining their relation to disease 
activity, severity and mode of therapy. 
 
METHODS 
This study was carried out in the Pediatric Allergy 
and Immunology Unit, Children’s Hospital, Ain 
Shams University. It included 46 patients fulfilling 
the American College of Rheumatology criteria for 
diagnosis of JRA 6. They were 31 females and 15 
males. Their ages ranged from 6 – 17 years with a 
mean of 12.4 ± 2.97 years and their disease duration 
ranged from 1 to 12 years with a mean of 5.26 ± 2.83 
years. They were grouped according to the type of 
disease onset into: 
* Group I: Comprised 30 children with polyarticular 
JRA. They were 20 females and 10 males. Their ages 
ranged from 7-16 years (mean 12.58 ± 2.9 years). 
Twenty-five patients were RF negative and only 5 
were RF positive. Ten children were studied during 
disease activity [based on clinical ground and ESR 
according to Pinals et al., (1981)] 7. The remaining 
20 children were studied during disease remission. 
All patients were receiving NSAIDs. In addition, 15 
of them were on low dose oral prednisone, 4 were on 
methotrexate (MTX) and 6 were receiving both MTX 
and oral prednisone. 
* Group II: Included 9 children with pauciarticular 
JRA. They were 6 females and 3 males. Their ages 
ranged from 7 – 16 years with a mean of 12 ± 3.3 
years. Eight out of the 9 patients were in disease 
remission at the time of the study, while only one was 
studied during disease activity. NSAIDs were the 
only line of therapy in 7 patients, whereas one patient 
was also receiving oral prednisone and one was 
receiving MTX. 
* Group III: Included 7 children with systemic-onset 
JRA (5 females and 2 males). Their ages ranged from 
8-16 years (mean 12.14 ± 3.23 years). One patient 
only was studied during disease activity. All patients 
were receiving NSAIDs. In addition, 4 of them were 
on oral prednisone and 3 were on MTX therapy.  
The range of doses of the received drugs was:  
- NSAIDs (ibuprofen): 10 – 40 mg/kg/day. 
- Oral prednisone: 0.25 – 1.5 mg/kg/day. 
- Methotrexate (MTX): 7 - 10 mg/m2/week either oral 
or IM. 
Two groups of children were studied as control 
subjects. 
Control group A: Included 13 patients with SLE 
attending the Pediatric Allergy and Immunology 
Clinic and diagnosed according to the (1982) revised 
criteria for the diagnosis of SLE 8. All had evidence 
of arthritis at the time of the study. They were 9 
females and 4 males and their ages ranged from 7-16 
years (mean 12.3 ± 3.66 years). 
Control group B: Comprised 32 healthy age and sex-
matched children. They were 21 females and 11 
males and their ages ranged from 7–16 years (mean 
12.56 ± 2.83 years). 
Methods 
Patients were subjected to: 
I) Clinical evaluation: with special emphasis on joint 
examination, systemic manifestations and current 
medications used.  
Three clinical indices of articular inflammation 
were used to evaluate each joint according to the 
American Rheumatism Medical Information System 
(ARAMIS, 1984) 9. They include joint swelling 
grades (0 = none, 1+ = mild synovial swelling or 
effusion with visible bony landmarks, 2+ = moderate 
swelling with definite obscuring of bony landmarks, 
3+ = severe swelling with no obvious landmarks), 
pain on motion and / or joint tenderness grades (0 = 
none, 1+ = mild pain with no subjective reaction, 2+ 
= moderate pain, 3+ = marked pain), and limitation 
of motion grades (0 = full range of motion, 1+ = 25% 
limitation, 2+ = 50% limitation, 3+ = 75% limitation, 
4+ = no motion possible).  
The mean for each of the 3 clinical indices of all 
joints was calculated. Joints examined were right and 
left metacarpophalangeal, proximal interphalangeal, 
distal interphalangeal, wrist, elbow, shoulder, 
temporo-mandibular, knee, ankle, small joints of the 
foot with exclusion of the sacroiliac and hip girdle 
joints. 
In addition to these indices, the total articular 
activity for each patient was then calculated 
considering the affected joints only as follows: 
Activity score 10,11 =   
1. Sum of the 3 clinical indices for each joint = X 
2. Sum of X of all examined joints Number of affected joints 
IgA and hidden RFs in JRA. 
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II) Laboratory investigations: (for patients and 
controls) 
Complete blood count (CBC) by Coulter Counter 
(Coulter Instruments, Model T660, Fullerton, 
California, USA), ESR (mm/1st hr) by Westergren 
method, CRP by latex agglutination test, ANA by 
indirect immunofluorescent microscopy. 
Assay for rheumatoid factors:  
- Classic IgM RF by latex agglutination method5. 
- IgA-RF by enzyme linked immunosorbent assay 
(ELISA) (Sigma Diagnostics, St. Louis, MO, 
USA)12,13.  
- Hidden RF by ion exchange chromatography 
(Sigma Chemical Co., St. Louis, MO, USA) 4,5.  
Three ml whole blood were aspirated and were 
allowed to clot at 37°C for ½ an hour and then 
centrifuged at 3000 rpm for 10 min. Serum was 
collected into a clean Ependorf’s tube and preserved 
at -20°C until assayed. Detection of hidden RF in the 
IgM fraction of the serum was done after separation 
of the serum at an acid pH. Results were expressed as 
positive or negative for hidden RF. 
Quantitative measurement of IgA-rheumatoid 
factor was assayed by ELISA. The microplate was 
coated with Fc fragment of highly purified human 
immunoglobulin G. A cut off value was taken at the 
95th percentile of healthy controls (23 mg/dL). 
Patients who had IgA-RF level above this value were 
considered to be positive for IgA-RF. 
III) Radiographic evaluation (of knees, hands and 
feet): 
X-ray films were taken at the time of sampling. 
Evaluation was done after the method of Rau and 
Herborn 14 for scoring soft tissue swelling, joint space 
narrowing, osteoporosis and erosions: 
0 Normal 
1 Soft tissue swelling and/or joint space 
narrowing/subchondral osteoporosis. 
2 Erosions with destruction of the joint surface 
(DJS) < 25%. 
3 DJS (26 – 50%). 
4 DJS (51 – 75%). 
5 DJS (> 75%). 
Joints examined radiologically were those of 
hands, feet and knees. A mean value of the score of 




The results were analyzed by commercially available 
software package (StatView, Abacus Concepts, Inc, 
Berkley, CA, USA). The data are presented as mean 
and standard deviation (SD). Student’s “t” test was 
used to compared between two groups as regards 
parametric data, whereas Mann Whitney test was 
used for non-parametric data. Pearson “r” correlation 
coefficient was used to determine the relationship 
between different quantitative variables. Chi-square 
test was used for contingency tables. For all tests, a 




All patients with JRA had significantly higher mean 
value of IgA-RF and positivity of hidden RF than 
both lupus and healthy controls. The results of lupus 
and healthy controls were comparable. On the other 
hand, patients with polyarticular JRA had 
significantly higher value of IgA-RF and positivity of 
hidden RF than patients with oligoarticular and 
systemic-onset disease. The results of patients with 
oligoarticular and systemic-onset disease were 
comparable (Table 1, Fig. 1 and 2). 
Classic IgM RF had only 10.9% sensitivity in 
diagnosing JRA. In contrast, IgA and hidden RFs had 
much higher sensitivities. The sensitivity of IgA-RF 
was 50% (76.7% for polyarticular JRA and 0% for 
both oligoarticular and systemic-onset disease), while 
the sensitivity of hidden RF was 56.5% (66.7%, 
33.3% and 42.9% for polyarticular, oligoarticular and 
systemic-onset disease respectively). Specificity, 
positive and negative predictive values of IgA and 
hidden RFs were (97.7%, 95.8% & 65.7%) for the 
former and (95.5%, 92.9% & 68.3%) for the latter. 
Combined positivity of both IgA and hidden RFs had 
100% specificity and positive predictive value for 
JRA, which were much higher than their sensitivity 
(43.5%) and negative predictive value (63.4%). 
 
Table (1): Comparison of mean IgA-RF and 
hidden RF positivity in all groups. 





All patients versus     
healthy controls 
4.49 < 0.001 21.64 < 0.001 
All patients versus        
lupus controls 
3.4 < 0.001 5.32 < 0.05 
Lupus controls versus 
healthy controls 
0.15 > 0.05 2.16 > 0.05 
Polyarticular versus 
oligoarticular 
2.9 < 0.05 5.64 < 0.05 
Polyarticular versus 
systemic-onset 
2.7 < 0.05 5.03 < 0.05 
Oligoarticular versus 
systemic-onset 
0.47 > 0.05 0.15 > 0.05 





































































Fig. (2): Percentage of positivity of hidden RF in different studied groups 
 
 
Classic IgM RF had no relation to disease 
activity and severity as evidenced by non-significant 
difference between values of activity score, ESR and 
Larsen index of patients with positive (5.5 ± 3.3, 22.7 
± 21.8 mm/1st hr and 1.9 ± 1.1) and those with 
negative classic RF (6.2 ± 0.4, 21 ± 2.2 mm/1st hr and 
2.2 ± 0.4) (p>0.05). In contrast, patients with active 
disease had significantly higher value of IgA-RF and 
positivity of hidden RF than patients with quiescent 
disease. In addition, IgA-RF correlated positively 
with activity score, ESR and Larsen index and 
correlated negatively with Hb. Also, patients with 
positive hidden RF had significantly higher mean 
values of activity score and Larsen index than those 
with negative hidden RF (Figures 3, 4 and 5). 
Steroid-treated JRA patients had significantly 
higher value of IgA-RF and positivity of hidden RF 
than non-steroid-treated patients (Fig. 6). 
There was significant positive association 
between IgA-RF and hidden RFs as 20 out of the 23 
IgA-RF positive patients had also positive hidden RF 
and 17 out of the 23 IgA-RF negative patients had 
negative hidden RF as well (Fig. 7). In addition, IgA-
RF level was significantly higher in patients with 
positive hidden RF than those with negative hidden 
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Fig. (3): IgA and hidden-RF in relation to disease 
status 
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Fig. (4): Correlation between IgA-RF and ESR, Hb, activity score and Larsen index in 














Activity score Larsen index
Hidden RF positive Hidden RF negative
 
z  =  3.84  z  =  3.57  
(p<0.001) (p<0.001) 
Fig. (5): Activity score and Larsen index in relation to hidden RF status 
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Hidden RF Positive Hidden RF Negative
IgA RF Positive IgA RF Negative  
X2 = 17.38, p< 0.001 
 




Rheumatoid factor detected by standard agglutination 
techniques is IgM and it is detected in a small 
subgroup of patients with JRA. Hidden RFs are IgM-
RFs detected in the IgM containing fraction after 
separation of the serum at an acid pH 4. Other RFs of 
IgA, IgG and IgE classes can also be identified by 
methods other than agglutination tests 2. 
In the present study, mean IgA-RF was 
significantly elevated in all JRA patients compared to 
the corresponding values of healthy and lupus 
controls. Similar findings were observed by 
Bharadwaj et al.3, who also found a non-significant 
difference between serum IgA level of patients with 
positive and those with negative IgA-RF indicating 
that the elevated IgA-RF was not secondary to a rise 
in the serum IgA level. In addition, IgA-RF was 
polymeric suggesting its local production in the 
mucosa. The prevalence of IgA-RF seropositivity 
among our studied JRA patients was 50%.  Previous 
researches reported a prevalence ranging from 22 – 
58% in one study 15 and 40.8% in another one 3.  
The prevalence of IgA-RF seropositivity was 
high in patients with polyarticular-onset disease 
(76.7%), whereas in patients with pauciarticular-
onset disease and in those with systemic-onset 
disease the prevalence of IgA-RF was 100% 
negative. Therefore, it can be deduced that IgA-RF is 
specific for JRA patients of the polyarticular variety 
and that its presence in the serum is not a pre-
requisite for joint or systemic manifestations of the 
inflammatory process in the other types of JRA. 
Walker et al. 16, reported IgA-RF positivity in 58% of 
patients with polyarticular-onset disease and in one 
only out of their 17 patients (5.9%) with 
pauciarticular JRA but it was negative in all 
systemic-onset disease patients. 
In the present study, the seropositivity to hidden 
RF was detected in 56.5% of all JRA patients. 
Previous investigators reported a prevalence quite 
near to ours and a prevalence of 68% was reported in 
2 of these earlier studies 5,17. The positivity of hidden 
RF was highest in JRA patients with polyarticular-
onset disease (66.7%) followed by patients with 
IgA and hidden RFs in JRA 
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systemic-onset disease (42.9%) and the least 
percentage was detected in patients with 
pauciarticular-onset disease (33.3%). Varbanova et 
al.18, reported hidden RF positivity in 55% of patients 
with polyarticular-onset disease and 42% of patients 
with pauciarticular-onset disease.  
Compared with the percentage of positivity of 
classic RF in the different types of JRA (16.67% in 
polyarticular-onset JRA and 0% in both the 
pauciarticular and systemic-onset types), hidden RF 
appears more reliable in the diagnosis. This is based 
on the fact that it was not only positive in those 
patients who were positive for classic RF, but it was 
also positive in 15/25 (60%) of those who were 
ranked as RF negative. 
Concerning the effect of disease activity on IgA-
RF, it was found that patients with active disease had 
significantly higher IgA-RF level than those with 
quiescent disease. Also, IgA-RF correlated positively 
with activity score, ESR and CRP. Similar findings 
were reported by previous two studies 1,3. The 95th 
percentile of IgA level in JRA patients with quiescent 
disease was as high as 135 mg/dl. All patients with 
active disease had IgA-RF level greatly above this 
value. This ranks IgA-RF as one of the most accurate 
laboratory markers for diagnosis and follow up of 
disease activity in JRA.  
A close relation between hidden RF positivity 
and disease activity was also observed as 91.7% of 
patients with active disease were seropositive for 
hidden RF compared to 44.1% only of patients with 
quiescent disease. Also, patients with positive hidden 
RF had significantly higher values of activity score 
and ESR when compared to the corresponding values 
of those with negative hidden RF. Similarly, Moore 
et al.5 and Walker et al.16, reported significant 
positive correlation between hidden RF and disease 
activity.  
In contrast, classic RF had no correlation with 
disease activity as evidenced by the non-significant 
difference between levels of activity score and ESR 
of JRA patients with positive and those with negative 
classic RF. These results lend support to the study of 
Vasiliauskiene et al.1.  
Although steroid therapy reduce the levels of 
immunoglobulins including RFs, in this study, 
patients who were on steroid therapy had 
significantly higher value of IgA-RF and hidden RF 
positivity when compared to those who did not 
receive this therapeutic modality. This may be 
explained by the fact that patients who were on 
steroid therapy had more severe disease than patients 
who did not receive steroids and this may be an 
indirect evidence of the relation between IgA and 
hidden RFs and disease severity. The latter 
assumption was supported by the positive correlation 
between IgA-RF and the studied clinical and 
radiological scores. This was also the case with 
hidden RF as patients with positive hidden RF had 
significant elevation of the clinical and radiological 
scores when compared to those with negative hidden 
RF. Bharadwaj et al. 3 reported higher prevalence of 
IgA-RF in children in the poor functional class and 
significant association of deforming joint disease 
with the presence of hidden RF. Houssien et al. 12 
reported that IgA-RF correlated positively with the 
subsequent onset of severe erosive disease.  
Evaluation of the efficacy of each of IgA and 
hidden RFs in the diagnosis of JRA revealed 
comparable results for both tests. Broadly speaking, 
each test alone had a high specificity and positive 
predictive value and a low sensitivity and negative 
predictive value indicating that they are good positive 
but not good negative tests. 
Combined positivity of IgA and hidden RFs was 
not found in the lupus control group. Furthermore, 
this combination was 100% specific for JRA patients, 
whereas the specificity of IgA and hidden RFs 
separately were 97.7% and 95.5% respectively. 
Similarly, Jonsson et al. 19 mentioned that combined 
positivity of IgA and hidden RFs was highly specific 
for RA. Therefore, the mutual evaluation of both 
types of RFs can help in settling the diagnosis of JRA 
in cases of doubt. 
In conclusion, IgA-RF and hidden RFs can be 
considered specific markers in diagnosing JRA. The 
former was essentially positive only in polyarticular-
onset JRA patients. Hidden RF was found in all the 3 
types of JRA but its positivity was highest among 
those with polyarticular-onset disease. The mutual 
evaluation of both IgA and hidden RFs was 
considered to be more reliable given the better 
overall performance of both tests together. Both 
markers had also significant positive correlation with 
disease activity, and disease severity, so we 
recommend their addition to the currently used tests 
of JRA to facilitate the diagnosis especially in 
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